Primary Insomnia Treatment Guidelines

Introduction to Treatment Options

The American Academy of Sleep Medicine recommends short-to-intermediate acting benzodiazepine receptor agonists (BzRAs), specifically zolpidem, eszopiclone, or zaleplon, as first-line pharmacological treatments for primary insomnia, with zolpidem and eszopiclone having the strongest evidence for both sleep onset and maintenance 1, 2, 3

Cognitive Behavioral Therapy for Insomnia (CBT-I) should be the initial treatment before any medication, as it demonstrates superior long-term outcomes with sustained benefits after discontinuation and no adverse effects 1, 3
CBT-I includes stimulus control therapy, sleep restriction therapy, relaxation therapy, and cognitive therapy 1

Zolpidem 10 mg (5 mg for elderly) reduces sleep latency and improves sleep maintenance with moderate-to-low quality evidence 2
Eszopiclone 3 mg (2 mg for elderly) has superior evidence for sleep maintenance 2
The American Academy of Sleep Medicine suggests that the choice between zolpidem and eszopiclone depends on the primary sleep complaint: zolpidem for sleep onset, eszopiclone for sleep maintenance, though both address both domains 3

Alternate BzRA or ramelteon if initial agent unsuccessful 1, 3
Low-dose doxepin 3-6 mg is particularly effective for sleep maintenance with minimal side effects 3
Sedating antidepressants (trazodone, amitriptyline, doxepin, mirtazapine) are reserved for comorbid depression/anxiety 1, 3

Traditional benzodiazepines (lorazepam, temazepam) have a higher risk of tolerance, dependence, falls, and cognitive impairment—especially in elderly 3
Atypical antipsychotics (quetiapine, olanzapine) are explicitly warned against for primary insomnia due to weak evidence and significant adverse effects including weight gain and metabolic syndrome 3
Over-the-counter antihistamines are not recommended due to lack of efficacy and safety data 1

Zolpidem and eszopiclone cause psychomotor and memory impairment 7.5-11.5 hours post-dose, even when patients don't subjectively perceive sedation 2
The FDA mandates dose reduction in women and elderly due to driving impairment risk 2
Patients should be followed every few weeks initially to assess effectiveness and side effects, and the lowest effective maintenance dose should be used 1
Gradual dose reduction when discontinuing to minimize withdrawal 1
Observational studies suggest hypnotic use may be associated with increased risk of dementia, fractures, and major injury, though causality is not established 2
Prescribe for shortest duration necessary with regular reassessment 1